Drug Profile
ES2B C001
Alternative Names: AV-001 - AdaptVac; ES2B-C001; ES2B-C001 (HER2-cVLP)Latest Information Update: 21 Apr 2023
Price :
$50
*
At a glance
- Originator AdaptVac
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical HER2 positive breast cancer
Most Recent Events
- 18 Apr 2023 Pharmacodynamics data from a preclinical study in Breast cancer released by ExpreS2ion Biotechnologies
- 14 Apr 2023 Pharmacodynamics and immunogenicity data from preclinical trial in HER2-positive-breast-cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 23 Jan 2023 ES2B C001 is still in preclinical phase for HER2-positive breast cancer in USA (AdaptVac pipeline; January 2023)